Cerus (CERS) to Release Quarterly Earnings on Tuesday

Key Points

• Cerus (CERS) is set to release its Q2 2025 earnings on August 5th, with analysts forecasting a loss of ($0.02) per share and revenues of $51.80 million.
• In the previous quarter, Cerus reported a loss of ($0.04) EPS against expectations of ($0.05) and generated revenue of $43.24 million, falling short of the $47.44 million estimate.
• Institutional investors bolster their positions, with nearly 78.37% of Cerus stock owned by hedge funds, including significant increases from AQR Capital Management and Cubist Systematic Strategies.

Cerus (NASDAQ:CERS - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 5th. Analysts expect Cerus to post earnings of ($0.02) per share and revenue of $51.80 million for the quarter.

Cerus (NASDAQ:CERS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. Cerus had a negative net margin of 10.23% and a negative return on equity of 34.81%. The company had revenue of $43.24 million during the quarter, compared to analyst estimates of $47.44 million. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Stock Up 1.2%

CERS stock traded up $0.02 during midday trading on Friday, reaching $1.30. The company had a trading volume of 263,264 shares, compared to its average volume of 1,313,387. The company has a market capitalization of $247.55 million, a P/E ratio of -12.95 and a beta of 1.56. The company has a 50 day moving average of $1.38 and a two-hundred day moving average of $1.48. The company has a current ratio of 2.32, a quick ratio of 1.63 and a debt-to-equity ratio of 1.15. Cerus has a 1 year low of $1.12 and a 1 year high of $2.54.

Hedge Funds Weigh In On Cerus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC raised its position in Cerus by 12.0% during the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company's stock valued at $4,479,000 after acquiring an additional 344,395 shares in the last quarter. AQR Capital Management LLC raised its position in Cerus by 291.6% during the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company's stock valued at $1,986,000 after acquiring an additional 1,064,133 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in Cerus by 152.4% during the first quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company's stock valued at $145,000 after acquiring an additional 62,854 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Cerus in the first quarter valued at approximately $32,000. Institutional investors own 78.37% of the company's stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.